2022
Utility of liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in lymphomas and plasma cell neoplasms.
Mata D, Shanmugam V, Decker B, Schrock A, Tukachinsky H, Williams E, Ross J, Montesion M, Oxnard G, Vergilio J, Xu M, Benhamida J. Utility of liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in lymphomas and plasma cell neoplasms. Journal Of Clinical Oncology 2022, 40: e19543-e19543. DOI: 10.1200/jco.2022.40.16_suppl.e19543.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaComprehensive genomic profilingNon-Hodgkin lymphomaPlasma cell neoplasmsPathogenic alterationsCell neoplasmsHybrid-capture next-generation sequencingLarge B-cell lymphomaRoutine clinical careActionable genomic alterationsGenomic alterationsHodgkin's lymphoma casesTumor biopsy specimensB-cell lymphomaPathogenic genomic alterationsUnique patient samplesRetrospective studyBiopsy specimensClinical careLymphoma casesTissue biopsiesLymphomaInsufficient tumorTumor DNAGenomic profiling
2021
High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis
Li P, Yuan J, Ahmed FS, McHenry A, Fu K, Yu G, Cheng H, Xu ML, Rimm DL, Pan Z. High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis. Frontiers In Oncology 2021, 11: 701492. PMID: 34527580, PMCID: PMC8435777, DOI: 10.3389/fonc.2021.701492.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaPD-L1 expressionMantle cell lymphomaKi67 proliferation rateOverall survivalPD-L1Cell lymphomaImmune checkpoint molecule PD-L1Low PD-L1 expressionLarge B-cell lymphomaX-tile softwareHigher Ki67 proliferation rateLog-rank testMCL casesNumber of M1Tissue microarray blocksB-cell lymphomaProliferation rateImmunophenotypic subclassificationInferior OSLow Ki67Better OSPoor OSPrognostic impactInferior prognosis
2019
Heterogeneous Genetic Alterations and Novel Pathogenic Pathways in Relapsed DLBCL Revealed By Whole Exome Sequencing
Ma J, Nie K, Inghirami G, Eng K, Elemento O, Au-Yeung R, Shen Y, Srivastava G, Gong J, Xu M, Tan L, Tam W. Heterogeneous Genetic Alterations and Novel Pathogenic Pathways in Relapsed DLBCL Revealed By Whole Exome Sequencing. Blood 2019, 134: 2770. DOI: 10.1182/blood-2019-125448.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaRelapsed diffuse large B-cell lymphomaWhole-exome sequencingPre-treatment tumorsVariant allele frequencyPre-treatment samplesAxonal guidance signalingRelapse samplesR-CHOPNormal controlsDLBCL cohortProgression-free survival ratesReceptor signalingExome sequencingLarge B-cell lymphomaFree survival rateFront-line treatmentILK signalingThird of patientsAryl hydrocarbon receptor signalingNovel therapeutic approachesB-cell lymphomaGuidance signalingNovel pathogenic pathwaysInstitutional review board
2015
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary
Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary. Oncotarget 2015, 6: 13933-13945. PMID: 26101854, PMCID: PMC4546442, DOI: 10.18632/oncotarget.4324.Peer-Reviewed Original ResearchConceptsEpstein-Barr virus-positive diffuse large B-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaYears of ageFrequent expressionOlder patientsAge cutoffMonoclonal B-cell proliferationArbitrary age cutoffsPoor performance statusGenetic featuresMore frequent expressionB cell proliferationPerformance statusYounger patientsClinicopathologic evidencePatient groupDLBCL patientsTreatment outcomesPatientsDLBCLGene expression profilingCD30Lymphoma
2014
Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital Tract
Ahmad AK, Hui P, Litkouhi B, Azodi M, Rutherford T, McCarthy S, Xu ML, Schwartz PE, Ratner E. Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital Tract. International Journal Of Gynecological Cancer 2014, 24: 1250-1255. PMID: 25010039, PMCID: PMC8139417, DOI: 10.1097/igc.0000000000000201.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDiagnosis, DifferentialDoxorubicinFemaleGenital Neoplasms, FemaleGynecologic Surgical ProceduresHumansLymphoma, Non-HodgkinMiddle AgedPrednisolonePrednisonePregnancyPregnancy Complications, NeoplasticRetrospective StudiesSurvival AnalysisTeniposideVincristineYoung AdultConceptsNon-Hodgkin lymphomaFemale genital tractGenital tractGynecologic malignanciesPara-aortic lymph nodesPrimary non-Hodgkin lymphomaDiffuse large B-cell lymphomaYale-New Haven HospitalLarge B-cell lymphomaConcomitant radiation therapyRadical gynecologic surgeryCommon histologic typeOverall median survivalSingle institution experienceStem cell transplantationRare gynecologic malignancyDiagnosis of lymphomaAnn Arbor systemB-cell lymphomaWorld Health OrganizationMedian survivalRecurrent diseaseCombination chemotherapyMedian ageUterine corpus
2013
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. Clinical Cancer Research 2013, 19: 3462-3473. PMID: 23674495, PMCID: PMC4102335, DOI: 10.1158/1078-0432.ccr-13-0855.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaAggressive B-cell lymphomasB-cell lymphomaPosttransplant lymphoproliferative disorderClassical Hodgkin lymphomaLarge B-cell lymphomaPD-L1Hodgkin's lymphomaT-cell/histiocyte-rich B-cell lymphomaExtranodal NK/T-cell lymphomaTissue biopsiesEBV-positive posttransplant lymphoproliferative disordersHistiocyte-rich B-cell lymphomaPD-1/PD-L1 pathwayNK/T-cell lymphomaPD-1/PD-L1Primary mediastinal large B-cell lymphomaNodular lymphocyte predominant Hodgkin lymphomaMixed cellularity classical Hodgkin lymphomaMediastinal large B-cell lymphomaCell death ligand 1Lymphocyte predominant Hodgkin lymphomaPD-L1 protein expressionPD-L1 expressionPD-L1 pathway